Cart
sales@molnova.com
2′,2′-Difluorodeoxyuridine
CAS No. 114248-23-6
2′,2′-Difluorodeoxyuridine( —— )
Catalog No. M35912 CAS No. 114248-23-6
2′,2′-Difluorodeoxyuridine (dFdU), the major metabolite of Gemcitabine, exhibits anticancer and antitumor activities, shows radiosensitization under hypoxic conditions, and can be used to study pancreatic cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 39 | In Stock |
|
| 5MG | 29 | In Stock |
|
| 10MG | 40 | In Stock |
|
| 25MG | 70 | In Stock |
|
| 50MG | 101 | In Stock |
|
| 100MG | 152 | In Stock |
|
| 200MG | 221 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name2′,2′-Difluorodeoxyuridine
-
NoteResearch use only, not for human use.
-
Brief Description2′,2′-Difluorodeoxyuridine (dFdU), the major metabolite of Gemcitabine, exhibits anticancer and antitumor activities, shows radiosensitization under hypoxic conditions, and can be used to study pancreatic cancer.
-
Description2′,2′-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026). 2′,2′-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorDrug Metabolite
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number114248-23-6
-
Formula Weight264.18
-
Molecular FormulaC9H10F2N2O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (473.16 mM; Ultrasonic ) H2O : 100 mg/mL (378.53 mM; Ultrasonic)
-
SMILESOC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)C(F)(F)[C@@H]1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pauwels B, et al. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol. 2006 Aug;58(2):219-28.?
molnova catalog
related products
-
GRGDSP TFA
GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor which can be used to modify the surface of cardiovascular implants such as vascular grafts to promote endothelialization.
-
Spastazoline
Spastazoline is a potent and selective inhibitor of spastin(Human spastin with IC50 of 99 nM ).?
-
4-Methylcatechol
4-methylcatechol is a metabolite of homoprotocatechuic acid. It is both a substrate and a suicide inhibitor of Catechol 23-dioxygenase. 4-methylcatechol is known to induce the production of brain-derived neurotrophic factor (BDNF). Recent studies have suggested that a lack of brain-derived neurotrophic factor (BDNF) in the limbic system may cause neuropathic pain.
